💨 Abstract

The World Health Organization (WHO) has prequalified Bavarian Nordic's mpox vaccine for adolescents aged 12-17, following EU approval. The decision aims to protect a vulnerable age group concerned by the global outbreak of mpox, a viral infection causing flu-like symptoms and skin lesions. Bavarian Nordic plans a clinical trial to assess the vaccine's safety in children aged 2-12.

Courtesy: theprint.in